BTOG 2023 | The targeted lung health check (TLHC) program in the UK

Robert Rintoul, MBChB, MRCP, PhD, FRCP, University of Cambridge & Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK, details the significance of the targeted lung health check (TLHC) program in the UK. Not only does it enable the earlier detection of lung cancer, but it provides an opportunity for the development of many biomarker studies which can enroll patients from this program. By studying how each biomarker might be employed optimally, the aim is to ultimately use biomarker tests alone or in conjunction with more traditional methods to help detect lung cancer at an early stage, while also minimizing cost for patients. Prof. Rintoul provides several examples of biomarkers and techniques being investigated such as protein biomarkers, ctDNA, breath analysis, and autoantibodies. He also notes several trials that have already transpired as a result of the program, such as the iDx Lung study, and the DART and SCOOT (NCT05368298) studies investigating the contribution AI could bring to his space. This interview took place at the British Thoracic Oncology Group (BTOG) Annual Conference 2023 in Belfast, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.